ETHYLMORPHINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H23NO3
Molecular Weight	313.3908
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCOC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)=C2[C@@]34CCN5C

InChI

InChIKey=OGDVEMNWJVYAJL-LEPYJNQMSA-N

InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C19H23NO3
Molecular Weight	313.3908
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Ethylmorphine is a derivative of morphine with analgesic and antitussive effect. It acts by activating the opioid receptors and thus has a direct influence on the CNS system. Ethylmorphine was approved in Europe for the treatment of dry cough (Codethyline, Dionine).

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Opioid receptors; mu/kappa/delta 33	Agonist 2,752		345.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cough 106	Primary		Approved 8,583	CODETHYLINE

C_max

Value	Dose	Co-administered	Analyte	Population
1.09 μM	1.5 mg/kg bw single, oral		ETHYLMORPHINE serum	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
222 μM × min	1.5 mg/kg bw single, oral		ETHYLMORPHINE serum	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.97 h	1.5 mg/kg bw single, oral		ETHYLMORPHINE serum	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
8.5 mg single, oral	healthy, 10 months	Other AEs: Sedation...
1.5 mg/kg single, oral	healthy, 24 years	Other AEs: Dizziness, Drowsiness...

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Sedation	grade 5	8.5 mg single, oral	healthy, 10 months
Loose stools	1 patient	1.5 mg/kg single, oral	healthy, 24 years
Dizziness	7 patients	1.5 mg/kg single, oral	healthy, 24 years
Drowsiness	slight, 2 patients	1.5 mg/kg single, oral	healthy, 24 years

Showing 1 to 4 of 4 entries

Previous1Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1,946		substrate 1,388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as victim

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2D6 1,388	substrate 4,014	yes
CYP3A4 1,946	substrate 4,014	yes

Showing 1 to 2 of 2 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ABI Chem	AC1Q37UW
Ambinter	Amb22801513	http://www.ambinter.com/reference/22801513
Angene	AGN-PC-0OHUE6
Aurora Fine Chemicals LLC	A17.879.672	http://online.aurorafinechemicals.com/info?ID=A17.879.672
Chemieliva Pharmaceutical Co., Ltd	PBCM1411510

Showing 1 to 5 of 23 entries

Previous1 2 3 4 5Next

PubMed

Show entries

Title	Date	PubMed
Acute renal failure due to concomitant action of methotrexate and indomethacin.	1986 Jun 14	2872506
[Effects of diclofenac sodium combined with dionine in cases with fibrinous membrane after intraocular lens implantation].	2001 Apr 28	12536644
Evidence for the presence of active cytochrome P450 systems in Schistosoma mansoni and Schistosoma haematobium adult worms.	2002 May 22	12023046
Enzyme immunoassay validation for the detection of buprenorphine in urine.	2003 Mar	12670004
Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms.	2005 Jan	15572279

Showing 1 to 5 of 9 entries

Previous1 2Next

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose in adults is 50 mg of codethyline per day, i.e. 10 tablets (1 tablet contains 5 mg of ethylmorphine hydrochloride) per day over several intakes, at a minimum of 4 hours apart. In children the normal dose is 1 tablet per intake, to be renewed after 6 hours if necessary, without exceeding 4 tablets per day.

Route of Administration: Oral

In Vitro Use Guide

Unknown